Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor-Expressing Salivary Gland Cancer: A Phase II Trial
Articolo
Data di Pubblicazione:
2021
Abstract:
The activity of androgen-deprivation therapy (ADT) in androgen receptor-positive (AR+) salivary gland carcinomas (SGCs) has been established in the past few years. Second-line treatment in castration-resistant patients is still unknown. We investigated the activity of abiraterone acetate as second-line treatment in ADT-resistant, AR+ patients with SGC.
Tipologia CRIS:
1.1 Articolo in rivista
Elenco autori:
Locati, Laura D; Cavalieri, Stefano; Bergamini, Cristiana; Resteghini, Carlo; Colombo, Elena; Calareso, Giuseppina; Mariani, Luigi; Quattrone, Pasquale; Alfieri, Salvatore; Bossi, Paolo; Platini, Francesca; Capone, Iolanda; Licitra, Lisa
Link alla scheda completa:
Link al Full Text:
Pubblicato in: